Date | Time | Source | Headline | Symbol | Company |
05/06/2024 | 7:00AM | PR Newswire (US) | Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 | NASDAQ:CGEN | Compugen Ltd |
04/25/2024 | 7:00AM | PR Newswire (US) | Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 | NASDAQ:CGEN | Compugen Ltd |
04/10/2024 | 7:00AM | PR Newswire (US) | Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 | NASDAQ:CGEN | Compugen Ltd |
04/03/2024 | 7:00AM | PR Newswire (US) | Compugen to Participate in Two Upcoming Investor Conferences | NASDAQ:CGEN | Compugen Ltd |
03/11/2024 | 7:00AM | PR Newswire (US) | Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy | NASDAQ:CGEN | Compugen Ltd |
03/06/2024 | 7:00AM | PR Newswire (US) | Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 | NASDAQ:CGEN | Compugen Ltd |
03/05/2024 | 4:06PM | Edgar (US Regulatory) | Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | NASDAQ:CGEN | Compugen Ltd |
03/05/2024 | 7:00AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CGEN | Compugen Ltd |
03/05/2024 | 7:00AM | PR Newswire (US) | Compugen Reports Fourth Quarter and Full Year 2023 Results | NASDAQ:CGEN | Compugen Ltd |
03/05/2024 | 6:05AM | IH Market News | U.S. Futures Dip, Crude Oil Fluctuates | NASDAQ:CGEN | Compugen Ltd |
02/26/2024 | 7:00AM | PR Newswire (US) | Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 | NASDAQ:CGEN | Compugen Ltd |
02/20/2024 | 7:00AM | PR Newswire (US) | Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 | NASDAQ:CGEN | Compugen Ltd |
02/15/2024 | 7:00AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CGEN | Compugen Ltd |
02/15/2024 | 7:00AM | PR Newswire (US) | Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer | NASDAQ:CGEN | Compugen Ltd |
01/08/2024 | 7:10AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CGEN | Compugen Ltd |
01/08/2024 | 7:05AM | PR Newswire (US) | Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer | NASDAQ:CGEN | Compugen Ltd |
01/08/2024 | 7:00AM | PR Newswire (US) | Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement | NASDAQ:CGEN | Compugen Ltd |
12/19/2023 | 9:30AM | AllPennyStocks.com | Strong Open For Biotech Following Exclusive Agreement Announcement | NASDAQ:CGEN | Compugen Ltd |
12/19/2023 | 7:12AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CGEN | Compugen Ltd |
12/19/2023 | 7:10AM | PR Newswire (US) | Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer | NASDAQ:CGEN | Compugen Ltd |
12/19/2023 | 7:05AM | PR Newswire (US) | Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology | NASDAQ:CGEN | Compugen Ltd |
12/19/2023 | 7:00AM | Business Wire | Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program | NASDAQ:CGEN | Compugen Ltd |
11/07/2023 | 7:00AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CGEN | Compugen Ltd |
11/07/2023 | 7:00AM | PR Newswire (US) | Compugen Reports Third Quarter 2023 Results | NASDAQ:CGEN | Compugen Ltd |
11/06/2023 | 7:00AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CGEN | Compugen Ltd |
11/06/2023 | 7:00AM | PR Newswire (US) | Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy | NASDAQ:CGEN | Compugen Ltd |
11/03/2023 | 4:35PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:CGEN | Compugen Ltd |
11/03/2023 | 4:35PM | PR Newswire (US) | Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification | NASDAQ:CGEN | Compugen Ltd |
10/31/2023 | 9:00AM | PR Newswire (US) | Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer | NASDAQ:CGEN | Compugen Ltd |
10/24/2023 | 7:00AM | PR Newswire (US) | Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023 | NASDAQ:CGEN | Compugen Ltd |